论文部分内容阅读
目的 评价左氧氟沙星治疗肺结核的疗效、适宜剂量和在我国应用的前景。方法 97例初治菌阳肺结核随机分为治疗组 ( 2HL2 V/4HL2 、50例 )和对照组 ( 2HL2 Z/4HL2 、4 7例 )进行短程化疗。结果 治疗组和对照组 2个月痰菌阴转率分别为 94 0 %和 83 0 % ;满疗程痰菌阴转率分别为 98 0 %和 97 9%。胸部X线所见 ,治疗组和对照组病灶吸收分别为 98 0 %和 95 7% ,两组分别有 73 1 %和 50 0 %的空洞闭合。治疗组和对照组不良反应发生率分别为 1 3 2 %和 7 8%。结论 左氧氟沙星是一种新的有效的、安全的抗结核药物。
Objective To evaluate the efficacy and appropriate dosage of levofloxacin in the treatment of pulmonary tuberculosis and the prospect of its application in China. Methods 97 cases of newly diagnosed bacillary positive pulmonary tuberculosis were randomly divided into treatment group (2HL2 V / 4HL2, 50 cases) and control group (2HL2 Z / 4HL2, 47 cases) for short-course chemotherapy. Results The sputum negative conversion rates were 94 0% and 83 0% for the two months in the treatment group and the control group, respectively. The full-course sputum negative conversion rates were 98 0% and 97 9%, respectively. Chest X-ray findings, treatment and control group lesions were 98 0% and 95 7%, respectively, 73 1% and 50 0% of the two groups were closed. Adverse reactions in the treatment group and control group were found to be 132% and 78%, respectively. Conclusion Levofloxacin is a new effective and safe anti-TB drug.